Hot Features
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying a... SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.28 | -7.86516853933 | 3.56 | 3.74 | 3.28 | 370529 | 3.46035822 | CS |
| 4 | -0.9 | -21.5311004785 | 4.18 | 4.5923 | 3.28 | 901706 | 3.83176631 | CS |
| 12 | -1.34 | -29.0043290043 | 4.62 | 4.7178 | 3.28 | 710574 | 3.8330892 | CS |
| 26 | -0.54 | -14.1361256545 | 3.82 | 5.15 | 3.28 | 563217 | 3.9398344 | CS |
| 52 | 1.45 | 79.2349726776 | 1.83 | 6.6 | 1.6 | 710053 | 3.17698422 | CS |
| 156 | 2.36 | 256.52173913 | 0.92 | 6.6 | 0.41 | 272677 | 3.04220753 | CS |
| 260 | -4.52 | -57.9487179487 | 7.8 | 12.09 | 0.3657 | 296262 | 2.90955986 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.